Fintel on MSN23h
Citigroup Initiates Coverage of Biogen (BIIB) with Neutral Recommendation
Fintel reports that on November 14, 2024, Citigroup initiated coverage of Biogen (NasdaqGS:BIIB) with a Neutral ...
Fintel on MSN23h
Wolfe Research Initiates Coverage of Biogen (BIIB) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Analysts at Citigroup
Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...
Los Angeles Capital Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB)
Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...
bovnews18h
What’s Driving Biogen Inc (BIIB) Stock’s -12.76% Plunge Over the Past Month?
On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Pharmabiz4h
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
STAT20h
Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
FiercePharma21h
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Japan Today14h
Japan approves 2nd protein-targeting drug for Alzheimer's sufferers
A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...